{
    "id": "dbpedia_8093_1",
    "rank": 7,
    "data": {
        "url": "https://www.linkedin.com/posts/olphaglobal_olpha-withinreach-activity-7209182164259622912-yJ5x",
        "read_more_link": "",
        "language": "en",
        "title": "Olpha on LinkedIn: #olpha #withinreach",
        "top_image": "https://media.licdn.com/dms/image/v2/D5605AQGlcxsNwzj0LQ/videocover-high/videocover-high/0/1718802962929?e=2147483647&v=beta&t=B-UlVzlrMjk3XZRXEDGcYthlArU1VjmGtGVJbabaMJA",
        "meta_img": "https://media.licdn.com/dms/image/v2/D5605AQGlcxsNwzj0LQ/videocover-high/videocover-high/0/1718802962929?e=2147483647&v=beta&t=B-UlVzlrMjk3XZRXEDGcYthlArU1VjmGtGVJbabaMJA",
        "images": [
            "https://media.licdn.com/dms/image/v2/D4D3DAQElY1ES61T9Ig/image-scale_191_1128/image-scale_191_1128/0/1718789335319/olphaglobal_cover?e=2147483647&v=beta&t=c-zzlYQZmZmsKbXEYaBsgkjBkzk55sQ-1CLsHxwIpdM"
        ],
        "movies": [
            "https://dms.licdn.com/playlist/vid/v2/D5605AQGlcxsNwzj0LQ/mp4-640p-30fp-crf28/mp4-640p-30fp-crf28/0/1718802965530?e=2147483647&v=beta&t=XpvLCb_0JKzkXlx9W8TSGq-b29ob7cWhw85gkUJxgfY"
        ],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Olpha"
        ],
        "publish_date": "2024-06-19T13:16:08.072000+00:00",
        "summary": "",
        "meta_description": "Starting today, Olainfarm is now Olpha! With our new name and brand, we are taking a bold step forward in our journey to transform from a regional player into…",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/olphaglobal_olpha-withinreach-activity-7209182164259622912-yJ5x",
        "text": "𝐒𝐭𝐫𝐢𝐝𝐞𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐠𝐞𝐭𝐬 𝐔𝐒𝐅𝐃𝐀 𝐧𝐨𝐝 𝐟𝐨𝐫 𝐏𝐫𝐞𝐠𝐚𝐛𝐚𝐥𝐢𝐧 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 📌 Strides pharma received permission from the United States Food and Drug Administration (USFDA) to sell a generic medicine for nerve pain. 📌Strides Pharma Global Pte Limited, a subsidiary of the business, has acquired approval from the US drug agency for Pregabalin capsules in various strengths (25 mg, 50 mg, 75 mg, 150 mg, 100 mg, 200 mg, 225 mg, and 300 mg). 📌The product is bioequivalent and therapeutically equivalent to Upjohn US's Lyrica pills, which are a Reference Listed Drug. The capsule is used to treat fibromyalgia. #stridespharma #usfda #anda #pregabalin\n\nRicky Lakhani, Daljit Cheema and Corina Feraru were excellent companions at #COGEurope and proved how people make the difference, and why you should be talking to us about how the #Pharmaseal #Medrio partnership can benefit your projects. #medrio #pharmaseal #eclinical #cdms\n\n🚨 𝗡𝗲𝘄 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲! Laprophan, the leading Moroccan laboratory, has emerged as a key player in the potential takeover of Recipharm. Laprophan, under the leadership of Dr. Farid Bennis, has presented a second \"firm\" offer, initiating a thirty-day exclusivity period that has captured the industry's attention. The surprising acceptance of the exclusivity period, expiring on March 29, has sidelined Astrea Pharma's bid, making Laprophan the imminent choice for Recipharm's future. As the deadline approaches, the question is to know how Laprophan's vision aligns with the future of Recipharm in Monts. We look forward to witnessing the impact that this collaboration may bring to the pharmaceutical landscape! 🌐 #PharmaceuticalIndustry #pharma\n\nDuring the discussion on Panel I: 'Drug prices in focus: The biggest challenges of drug manufacturers in Bosnia and Herzegovina', we analyze and investigate the pharmaceutical sector and how it faces new challenges. On the panel, we talked with Dr. Aziz Šukalo, director of the BiH Region/market support sector director, Bosnalijek BiH, Benjamin Sahovic, president of the Management Board, FARMAVITA, and Saša Urošević, GM, HEMOFARM BiH. \"The supply chain and the global functioning of the health sector were disrupted - then by the pandemic, and now in the world, and this greatly affects the medicine market in the Adria region,\" Šahović said. #pharmacy #pandemia #bloombergadria #conference\n\nThis week's Pearce IP #BioBlast features the following: - Amgen appeals Alexion Pharmaceuticals, Inc.’s preliminary injunction order regarding off-label use of #eculizumab (Soliris®) biosimilar Bekemv® in Germany - FDA publishes draft guidance for biosimilar supplement classifications - Fresenius Kabi & Formycon AG settle with Johnson & Johnson in US over #ustekinumab enabling sales from no later than 15 April 2025 - Biocon confirms Viatris North American transition will complete by end Q3 2023 - Economic Development Bank For Puerto Rico grants $3.85M to Biosimilar Sciences and OcyonBio - UPC appoints 21 additional judges - Coherus BioSciences’ Q2 2023 financial results show quadrupling of #ranibizumab sales since last quarter Read more: https://lnkd.in/gxFknvtm #bioblast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma\n\nSTADA Eurasia aids to the open dialogue between the regulators of Kazakhstan and the international pharmaceutical industry at “GLOBAL PHARM 2023” held in Astana on Oct. 26th. During the annual round table with CEOs Arminas Macevicius , VP STADA Eurasia, voiced the need to be faster and more agile in taking decisions on streamlining market access of modern biosimilars to cover more patients and to improve the quality of their lives. #STADA #STADAEurasia\n\n#Imagine patients facing their illnesses without worrying if and when they will be experiencing pain, refraining them from living an active life. At Lavipharm, we imagined this and turned our vision into reality. We continue to invest in pain management. EFPIA - European Federation of Pharmaceutical Industries and Associations ΣΦΕΕ / SFEE - Σύνδεσμος Φαρμακευτικών Επιχειρήσεων Ελλάδος #WeWontRest #SFEE #EFPIA #Lavipharm #PainManagement\n\nThis is a story of success 2014 - Validation of the Olon #Daptomycin process 2017 - Launch of Olon Daptomycin in the US market, first API supplier to launch generic Daptomycin 2018 - Launch of Olon Daptomycin in Europe, first API supplier to launch generic Daptomycin 2024 - Olon makes investments towards significant expansion, reaching double its production capacity We celebrate 10 years of #Olon Daptomycin, announcing doubled production capacity #pharmasupplychain #pharma"
    }
}